A practical nomogram for predicting coronary thrombosis for Kawasaki disease patients with medium or large coronary artery aneurysm.
Clinical variables
Coronary artery aneurysm
Kawasaki disease
Nomogram
Predictive value
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
29
07
2022
accepted:
09
09
2022
medline:
1
8
2023
pubmed:
24
9
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
Kawasaki disease (KD) is the main cause of acquired heart disease in children. Coronary thrombosis is a serious cardiovascular complication of KD, which affects the long-term treatment effect. The purpose was to develop and validate a model for predicting coronary thrombosis in KD with medium or large coronary artery aneurysm (CAA). A total of 358 consecutive KD patients with medium or large CAA from Chongqing Children's Hospital were enrolled retrospectively. The demographic data, clinical characteristics, laboratory features before intravenous immunoglobulin (IVIG) treatment, and all radiological features during hospitalization and follow-up were collected. Eligible patients follow-up for > 2 years. Follow-up was weekly for the first 1 month, monthly for the next 11 months, and every 3-6 months after 1 year. The main examinations included echocardiogram and electrocardiogram. The primary endpoint was defined as coronary thrombosis during the follow-up. Coronary thrombosis was assessed by echocardiographic assessment of the presence of echoes in the lumen of the right coronary artery, left main coronary artery, left anterior descending artery, or left circumflex artery by echocardiologists. The independent risk factors were identified using univariate analyses and multivariate logistic regression analyses, and the nomogram was constructed for predicting coronary thrombosis. Tenfold cross-validation was used to perform internal validation. The area under the ROC curve (AUC), calibration curve, and decision curve analysis were used to evaluate the discrimination, calibration, and clinical utility of the nomogram, respectively. Multivariate logistic regression analysis revealed that male (odds ratio [OR] 3.491; 95% confidence interval [CI] 1.570-7.765), large CAA (OR 3.725; 95% CI 1.388-9.999), no use high-dose aspirin prior to IVIG (OR 3.114; 95% CI 1.291-7.510), two-vessel coronary artery involvement (OR 4.433; 95% CI 1.732-11.344), three-vessel coronary artery involvement (OR 5.417; 95% CI 2.048-14.328), four-vessel coronary artery involvement (OR 13.183; 95% CI 3.408-50.997), serum fibrinogen level > 5.325 g/L (OR 14.233; 95% CI 5.479-36.921), serum thrombin time level ≤ 15.15 s (OR 3.576; 95% CI 1.756-7.284) were significantly associated with coronary thrombosis. The nomogram was established based on these variables. The AUC of the nomogram were 0.920, and tenfold cross-validation (repeated 100 times) showed that the average AUC was 0.902. Moreover, the nomogram had a well-fitted calibration curve and also exhibited good clinical usage. The nomogram is based on six ready-made clinical variables, is easy to use, has excellent diagnostic performance, and can help clinicians make better clinical decisions on the management and treatment of KD patients with medium or large CAA.
Identifiants
pubmed: 36151486
doi: 10.1007/s10238-022-00893-2
pii: 10.1007/s10238-022-00893-2
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1317-1324Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Cohen E, Sundel R. Kawasaki disease at 50 years. JAMA Pediatr. 2016;170(11):1093–9.
doi: 10.1001/jamapediatrics.2016.1446
pubmed: 27668809
Sosa T, Brower L, Divanovic A. Diagnosis and management of Kawasaki disease. JAMA Pediatr. 2019;173(3):278–9.
doi: 10.1001/jamapediatrics.2018.3307
pubmed: 30667467
Wu MH, Chen HC, Yeh SJ, Lin MT, Huang SC, Huang SK. Prevalence and the long-term coronary risks of patients with Kawasaki disease in a general population <40 years: a national database study. Circ Cardiovasc Qual Outcomes. 2012;5:566–70.
doi: 10.1161/CIRCOUTCOMES.112.965194
pubmed: 22589296
Miura M, Kobayashi T, Kaneko T, et al. Association of severity of coronary artery aneurysms in patients With Kawasaki disease and risk of later coronary events. JAMA Pediatr. 2018;172(5):e180030.
doi: 10.1001/jamapediatrics.2018.0030
pubmed: 29507955
pmcid: 5875323
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–99.
doi: 10.1161/CIR.0000000000000484
pubmed: 28356445
John B, Gordon JC. Management of sequelae of Kawasaki disease in adults. Glob Cardiol Sci Pract. 2017;2017(3):e201731.
Harada M, Akimoto K, Ogawa S, et al. National Japanese survey of thrombolytic therapy selection for coronary aneurysm: intracoronary thrombolysis or intravenous coronary thrombolysis in patients with Kawasaki disease. Pediatr Int. 2013;55(6):690–5.
doi: 10.1111/ped.12187
pubmed: 23919576
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation. 2017;135(17):e927–99.
doi: 10.1161/CIR.0000000000000484
pubmed: 28356445
McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, Vetter VL, Gersony WM, Mitchell PD, Newburger JW, et al. Pediatric heart network investigators. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007;116:174–9.
doi: 10.1161/CIRCULATIONAHA.107.690875
pubmed: 17576863
Ohkubo T, Fukazawa R, Ikegami E, Ogawa S. Reduced shear stress and disturbed flow may lead to coronary aneurysm and thrombus formations. Pediatr Int. 2007;49:1–7.
doi: 10.1111/j.1442-200X.2007.02312.x
pubmed: 17250496
Kuramochi Y, Ohkubo T, Takechi N, Fukumi D, Uchikoba Y, Ogawa S. Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease. Pediatr Int. 2000;42:470–5.
doi: 10.1046/j.1442-200x.2000.01270.x
pubmed: 11059533
Hamaoka K, Onouchi Z, Kamiya Y, Sakata K. Evaluation of coronary flow velocity dynamics and flow reserve in patients with Kawasaki disease by means of a Doppler guide wire. J Am Coll Cardiol. 1998;31:833–40.
doi: 10.1016/S0735-1097(98)00019-9
pubmed: 9525556
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status. Postgrad Med. 2018;130(4):442–7.
doi: 10.1080/00325481.2018.1468712
pubmed: 29745742
Muta H, Ishii M, Yashiro M, Uehara R, Nakamura Y. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics. 2012;129(2):e291–7.
doi: 10.1542/peds.2011-1704
pubmed: 22250032
Friedman KG, Gauvreau K, Hamaoka-Okamoto A, et al. Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US population. J Am Heart Assoc. 2016;5:e003289.
doi: 10.1161/JAHA.116.003289
pubmed: 27633390
pmcid: 5079009
Nakamura Y, Aso E, Yashiro M, et al. Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009. J Epidemiol. 2013;23(6):429–34.
doi: 10.2188/jea.JE20130048
pubmed: 24042393
Rife E, Gedalia A. Kawasaki disease: an update. Curr Rheumatol Rep. 2020;22(10):75.
doi: 10.1007/s11926-020-00941-4
pubmed: 32924089
pmcid: 7487199
Souilhol C, Serbanovic-Canic J, Fragiadaki M, et al. Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes. Nat Rev Cardiol. 2020;17(1):52–63.
doi: 10.1038/s41569-019-0239-5
pubmed: 31366922
Avtaeva YuN, Mel’nikov IS, Gabbasov ZA. Real-time recording of platelet adhesion to fibrinogen-coated surface under flow conditions. Bull Exp Biol Med. 2018;165(1):157–60.
doi: 10.1007/s10517-018-4119-5
pubmed: 29796802
Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894–904.
doi: 10.1111/j.1538-7836.2005.01365.x
pubmed: 16102057